



## Clinical trial results:

### A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)

#### Summary

EudraCT number	2015-001718-80
Trial protocol	NL FR DE IT
Global end of trial date	10 July 2020

#### Results information

Result version number	v2
This version publication date	25 August 2021
First version publication date	16 July 2021
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	BO42355
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01981850
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 July 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	10 July 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Stage 1: The main objective of this part of the study was to evaluate the efficacy of two different dose schedules of single-agent RO7490677 or RO7490677 in combination with ruxolitinib in participants with PMF, post-PV MF, or post ET-MF.

Stage 2: The main objective of this part of the study was to determine the effect size of three different doses of RO7490677 on the reduction in bone marrow fibrosis by  $\geq 1$  grade in participants with PMF, post-PV MF, or post ET-MF.

Protection of trial subjects:

All study subjects were required to read and sign and Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 October 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 8
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Israel: 6
Country: Number of subjects enrolled	Italy: 9
Country: Number of subjects enrolled	Netherlands: 9
Country: Number of subjects enrolled	United Kingdom: 8
Country: Number of subjects enrolled	United States: 78
Worldwide total number of subjects	124
EEA total number of subjects	24

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	26
From 65 to 84 years	95
85 years and over	3

## Subject disposition

### Recruitment

Recruitment details:

A total of 125 participants were enrolled at sites in 8 different countries.

### Pre-assignment

Screening details:

One randomized participant in Stage 2 did not receive the study treatment, bringing the total number of treated participants to 124.

### Period 1

Period 1 title	Main Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)

Arm description:

Participants who received no treatment for Myelofibrosis (MF) in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 milligram per kilogram (mg/kg) administered as a 30 minute intravenous (IV) infusion on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Arm type	Experimental
Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered 10 milligrams per kilogram (mg/kg) of PRM-151 QW via intravenous (IV) infusion.

<b>Arm title</b>	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)
------------------	---

Arm description:

Participants who received no treatment for MF in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

Arm type	Experimental
Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered 10 mg/kg of PRM-151 Q4W via IV infusion.

<b>Arm title</b>	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib
------------------	--

Arm description:

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and

Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Arm type	Experimental
Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered 10 mg/kg of PRM-151 QW via IV infusion.

Investigational medicinal product name	Ruxolitinib
Investigational medicinal product code	
Other name	Jakafi
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants who received ruxolitinib continued to take ruxolitinib orally twice a day at the dose at which they entered the study.

<b>Arm title</b>	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
------------------	--

Arm description:

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

Arm type	Experimental
Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered 10 mg/kg of PRM-151 Q4W via IV infusion and daily oral ruxolitinib.

Investigational medicinal product name	Ruxolitinib
Investigational medicinal product code	
Other name	Jakafi
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants who received ruxolitinib continued to take ruxolitinib orally twice a day at the dose at which they entered the study.

<b>Arm title</b>	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W
------------------	--

Arm description:

Participants were treated with single agent PRM-151 at a dose of 0.3 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Arm type	Experimental
Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered 0.3 mg/kg of PRM-151 Q4W via IV infusion.

<b>Arm title</b>	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W
Arm description:	
Participants were treated with single agent PRM-151 at a dose of 3.0 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.	
Arm type	Experimental
Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered 3 mg/kg of PRM-151 Q4W via IV infusion.

<b>Arm title</b>	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Arm description:	
Participants were treated with single agent PRM-151 at a dose of 10 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.	
Arm type	Experimental
Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered 10 mg/kg of PRM-151 Q4W via IV infusion.

<b>Number of subjects in period 1</b>	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib
Started	8	7	6
Completed	5	5	4
Not completed	3	2	2
Consent withdrawn by subject	1	-	-
Adverse Event	-	-	-
Death	2	-	-
Progressive Disease	-	-	-
Various reasons	-	-	2
Lack of efficacy	-	2	-

<b>Number of subjects in period 1</b>	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W
Started	6	33	32
Completed	6	20	16
Not completed	0	13	16
Consent withdrawn by subject	-	4	3

Adverse Event	-	6	5
Death	-	-	-
Progressive Disease	-	-	6
Various reasons	-	2	-
Lack of efficacy	-	1	2

Number of subjects in period 1	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Started	32
Completed	15
Not completed	17
Consent withdrawn by subject	3
Adverse Event	7
Death	-
Progressive Disease	6
Various reasons	1
Lack of efficacy	-

## Period 2

Period 2 title	Open Label Extension
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	OLE Stage 1: RO7490677 10 mg/kg IV Q4W

### Arm description:

Participants who completed the main phase of treatment moved to the open label extension. They were treated with single agent PRM-151 at a dose of 10 mg/kg administered as an IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle.

Arm type	Experimental
Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

### Dosage and administration details:

Participants were administered 10 mg/kg of PRM-151 Q4W via IV infusion.

<b>Arm title</b>	OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib
------------------	--

### Arm description:

Participants who completed the main phase of treatment moved to the open label extension. They were treated with PRM-151 at a dose of 10 mg/kg administered as an IV infusion in combination with daily oral ruxolitinib on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Ruxolitinib
Investigational medicinal product code	
Other name	Jakafi
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants who received ruxolitinib continued to take ruxolitinib orally twice a day at the dose at which they entered the study.

Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered 10 mg/kg of PRM-151 Q4W via IV infusion.

<b>Arm title</b>	OLE Stage 2: RO7490677 10 mg/kg IV Q4W
------------------	--

Arm description:

Participants who completed 9 cycles of the originally assigned treatment could switch to the open label extension. Participants enrolled received PRM-151 at a dose of 10mg/kg Q4W on days 1, 3, and 5 of first cycle of the open label phase and Day 1 of each subsequent 28 day cycle.

Arm type	Experimental
Investigational medicinal product name	PRM-151
Investigational medicinal product code	
Other name	recombinant human pentraxin-2
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered 10 mg/kg of PRM-151 Q4W via IV infusion.

<b>Number of subjects in period 2<sup>[1]</sup></b>	OLE Stage 1: RO7490677 10 mg/kg IV Q4W	OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib	OLE Stage 2: RO7490677 10 mg/kg IV Q4W
Started	13	5	48
Completed	1	0	0
Not completed	12	5	48
Consent withdrawn by subject	-	-	8
Adverse Event	2	1	8
Progressive Disease	3	2	9
Various reasons	3	1	3
Lost to follow-up	-	-	1
Lack of efficacy	4	1	19

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Not all participants who completed the Main Phase entered the OLE.



## Baseline characteristics

### Reporting groups

Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)
Reporting group description: Participants who received no treatment for Myelofibrosis (MF) in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 milligram per kilogram (mg/kg) administered as a 30 minute intravenous (IV) infusion on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.	
Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)
Reporting group description: Participants who received no treatment for MF in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.	
Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib
Reporting group description: Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.	
Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Reporting group description: Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.	
Reporting group title	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W
Reporting group description: Participants were treated with single agent PRM-151 at a dose of 0.3 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.	
Reporting group title	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W
Reporting group description: Participants were treated with single agent PRM-151 at a dose of 3.0 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.	
Reporting group title	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Reporting group description: Participants were treated with single agent PRM-151 at a dose of 10 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.	

Reporting group values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib
Number of subjects	8	7	6
Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0

Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	4	1	1
From 65-84 years	3	6	5
85 years and over	1	0	0
Age Continuous			
Participants in the Main Phase			
Units: years			
arithmetic mean	64.3	70.7	66.0
standard deviation	± 11.4	± 6.3	± 7.3
Gender Categorical			
Units: Subjects			
Female	5	2	3
Male	3	5	3
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	1
Asian	0	0	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	1	0	1
White	7	7	3
More than one race	0	0	0
Unknown or Not Reported	0	0	0

Reporting group values	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W
Number of subjects	6	33	32
Age Categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	6	5
From 65-84 years	3	27	27
85 years and over	0	0	0
Age Continuous			
Participants in the Main Phase			
Units: years			
arithmetic mean	66.2	70.6	70.2
standard deviation	± 8.6	± 7.1	± 6.5
Gender Categorical			
Units: Subjects			
Female	5	16	8
Male	1	17	24

Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	1
White	6	33	29
More than one race	0	0	0
Unknown or Not Reported	0	0	1

<b>Reporting group values</b>	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	Total	
Number of subjects	32	124	
Age Categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	6	26	
From 65-84 years	24	95	
85 years and over	2	3	
Age Continuous			
Participants in the Main Phase			
Units: years			
arithmetic mean	69.4		
standard deviation	± 8.9	-	
Gender Categorical			
Units: Subjects			
Female	11	50	
Male	21	74	
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	1	
Asian	2	4	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	0	3	
White	29	114	
More than one race	0	0	
Unknown or Not Reported	1	2	

## End points

### End points reporting groups

Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)
-----------------------	---

#### Reporting group description:

Participants who received no treatment for Myelofibrosis (MF) in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 milligram per kilogram (mg/kg) administered as a 30 minute intravenous (IV) infusion on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)
-----------------------	---

#### Reporting group description:

Participants who received no treatment for MF in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib
-----------------------	--

#### Reporting group description:

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
-----------------------	--

#### Reporting group description:

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

Reporting group title	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W
-----------------------	--

#### Reporting group description:

Participants were treated with single agent PRM-151 at a dose of 0.3 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Reporting group title	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W
-----------------------	--

#### Reporting group description:

Participants were treated with single agent PRM-151 at a dose of 3.0 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Reporting group title	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W
-----------------------	---

#### Reporting group description:

Participants were treated with single agent PRM-151 at a dose of 10 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Reporting group title	OLE Stage 1: RO7490677 10 mg/kg IV Q4W
-----------------------	--

#### Reporting group description:

Participants who completed the main phase of treatment moved to the open label extension. They were treated with single agent PRM-151 at a dose of 10 mg/kg administered as an IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle.

Reporting group title	OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib
-----------------------	--

#### Reporting group description:

Participants who completed the main phase of treatment moved to the open label extension. They were treated with PRM-151 at a dose of 10 mg/kg administered as an IV infusion in combination with daily oral ruxolitinib on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle.

Reporting group title	OLE Stage 2: RO7490677 10 mg/kg IV Q4W
-----------------------	--

#### Reporting group description:

Participants who completed 9 cycles of the originally assigned treatment could switch to the open label extension. Participants enrolled received PRM-151 at a dose of 10mg/kg Q4W on days 1, 3, and 5 of

first cycle of the open label phase and Day 1 of each subsequent 28 day cycle.

Subject analysis set title	Main Phase + OLE Stage 1: RO7490677 10 mg/kg IV QW
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Subject analysis set title	Main Phase + OLE Stage 1: RO7490677 10 mg/kg IV Q4W
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Subject analysis set title	Main Phase+OLE Stg. 1: RO7490677 10 mg/kg IV QW+Ruxolitinib
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who received no treatment for Myelofibrosis (MF) in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 milligram per kilogram (mg/kg) administered as a 30 minute intravenous (IV) infusion on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Subject analysis set title	Main Phase+OLE Stg. 1: RO7490677 10 mg/kg IV Q4W+Ruxolitinib
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who received no treatment for MF in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

Subject analysis set title	Main Phase +OLE Stage 2: RO7490677 0.3 mg/kg IV Q4W
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were treated with single agent PRM-151 at a dose of 0.3 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Subject analysis set title	Main Phase + OLE Stage 2: RO7490677 3 mg/kg IV Q4W
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were treated with single agent PRM-151 at a dose of 3.0 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Subject analysis set title	Main Phase + OLE Stage 2: RO7490677 10 mg/kg IV Q4W
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who completed 9 cycles of the originally assigned treatment could switch to the open label extension. Participants enrolled received PRM-151 at a dose of 10mg/kg Q4W on days 1, 3, and 5 of first cycle of the open label phase and Day 1 of each subsequent 28 day cycle.

### Primary: Stage 1 Main Phase: Overall Response Rate (ORR)

End point title	Stage 1 Main Phase: Overall Response Rate (ORR) <sup>[1][2]</sup>
-----------------	---

End point description:

ORR was defined as the percent of participants with a response according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. This was defined as those participants who achieved clinical improvement (CI), partial remission (PR), or complete remission (CR) at a post-baseline assessment of treatment response OR had at least stable disease (SD) for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time

point during the period of stable disease. The all treated population included all participants who received at least one dose of RO7490667.

End point type	Primary
----------------	---------

End point timeframe:

Up until and including completion of 6 cycles. Each cycle is 28 days.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: For stage 1, the hypothesis test was performed separately in each of the 4 treatment groups and overall, each at 5% significance level (one-sided; statistical significance was concluded if the lower bound of the 2 sided 90% CI was above 10%).

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6
Units: Percentage of Participants				
number (confidence interval 90%)	37.5 (11.11 to 71.08)	14.3 (0.73 to 52.07)	33.3 (6.28 to 72.87)	50.0 (15.32 to 84.68)

## Statistical analyses

No statistical analyses for this end point

## Primary: Stage 2 Main Phase: Bone Marrow Response Rate (BMRR)

End point title	Stage 2 Main Phase: Bone Marrow Response Rate (BMRR) <sup>[3][4]</sup>
-----------------	--

End point description:

Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria from baseline to any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy. The all treated population included all participants randomized and who received at least one administration of the drug.

End point type	Primary
----------------	---------

End point timeframe:

Up until and including completion of 9 cycles. Each cycle is 28 days.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: For stage 2, two pairwise comparisons (3 mg/kg vs 0.3 mg/kg and 10 mg/kg vs 0.3 mg/kg) were computed with aim to demonstrate superiority and therefore, used an adjusted two-sided level of significance of 0.025. The third comparison (10 mg/kg vs 3 mg/kg) was not expected to have enough power to demonstrate any difference with the planned sample size. This comparison was considered exploratory and was conducted using an unadjusted two-sided 0.05 level of significance.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

<b>End point values</b>	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	32	32	
Units: Percentage of Participants				
number (confidence interval 95%)	30.3 (14.62 to 45.98)	31.3 (15.19 to 47.31)	25.0 (10.00 to 40.00)	

## Statistical analyses

No statistical analyses for this end point

### Primary: Stage 1 Main + Open-Label Extension (OLE): ORR

End point title	Stage 1 Main + Open-Label Extension (OLE): ORR <sup>[5]</sup>
-----------------	---

End point description:

ORR was defined as the percent of participants with a response according to the IWG-MRT criteria. This was defined as those participants who achieved CI, PR, or CR at a post-baseline assessment of treatment response OR had at least SD for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease. The all treated population included all participants who received at least one dose of RO7490667.

End point type	Primary
----------------	---------

End point timeframe:

From cycle 6 day 29 up until study discontinuation or study termination. Each cycle is 28 days.

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: For stage 1, the hypothesis test was performed separately in each of the 4 treatment groups and overall, each at 5% significance level (one-sided; statistical significance was concluded if the lower bound of the 2 sided 90% CI was above 10%).

<b>End point values</b>	Main Phase + OLE Stage 1: RO7490677 10 mg/kg IV QW	Main Phase + OLE Stage 1: RO7490677 10 mg/kg IV Q4W	Main Phase+OLE Stg. 1: RO7490677 10 mg/kg IV QW+Ruxolitinib	Main Phase+OLE Stg. 1: RO7490677 10 mg/kg IV Q4W+Ruxolitinib
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	7	6	6
Units: Percentage of Participants				
number (confidence interval 90%)	50.0 (19.29 to 80.71)	71.4 (34.13 to 94.66)	50.0 (15.32 to 84.68)	66.7 (27.13 to 93.72)

## Statistical analyses

No statistical analyses for this end point

### Primary: Stage 2 Main + Open-Label Extension (OLE): BMRR

End point title	Stage 2 Main + Open-Label Extension (OLE): BMRR <sup>[6]</sup>
-----------------	--

**End point description:**

Defined as the percent of participants with a reduction in bone marrow fibrosis score by at least one grade according to WHO criteria at any time during the study. As determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy. The all treated population included all participants randomized and who received at least one administration of the drug.

End point type	Primary
----------------	---------

**End point timeframe:**

From cycle 9 day 29 up until study discontinuation or study termination. Each cycle is 28 days.

**Notes:**

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: For stage 2, two pairwise comparisons (3 mg/kg vs 0.3 mg/kg and 10 mg/kg vs 0.3 mg/kg) were computed with aim to demonstrate superiority and therefore, used an adjusted two-sided level of significance of 0.025. The third comparison (10 mg/kg vs 3 mg/kg) was not expected to have enough power to demonstrate any difference with the planned sample size. This comparison was considered exploratory and was conducted using an unadjusted two-sided 0.05 level of significance.

End point values	Main Phase +OLE Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase + OLE Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase + OLE Stage 2: RO7490677 10 mg/kg IV Q4W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	33	32	32	
Units: Percentage of Participants				
number (confidence interval 95%)	30.3 (14.62 to 45.98)	34.4 (17.92 to 50.83)	25.0 (10.00 to 40.00)	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Stage 1 Main Phase: BMRR**

End point title	Stage 1 Main Phase: BMRR <sup>[7]</sup>
-----------------	---

**End point description:**

Bone marrow response was defined as a reduction in bone marrow fibrosis score by at least one grade from baseline at anytime during the study. The all treated population included all participants who received at least one dose of RO7490667.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Baseline, Weeks 12 and 24

**Notes:**

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6



Units: Percentage of Participants				
number (confidence interval 95%)	37.5 (3.95 to 71.05)	14.3 (0.00 to 40.21)	16.7 (0.00 to 46.49)	50.0 (9.99 to 90.01)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Stage 1 Main Phase: Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Changes

End point title	Stage 1 Main Phase: Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Changes <sup>[8]</sup>
-----------------	--

End point description:

The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable. The values reported are the change from baseline scores. The all treated population included all participants who received at least one dose of RO7490667.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, beginning of each cycle (Cycle 2 onward). Each cycle is 28 days.

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6
Units: Score on a scale				
arithmetic mean (standard deviation)				
Baseline (n= 8,7,6,6)	23.1 (± 19.1)	16.9 (± 7.2)	26.8 (± 17.1)	15.3 (± 10.4)
Cycle(C) 2 Day(D) 1 (n= 7,6,6,6)	-5.3 (± 12.6)	5.7 (± 11.8)	0.5 (± 8.8)	-2.0 (± 5.0)
C3D1 (n= 7,7,6,5)	-9.1 (± 10.9)	1.9 (± 5.3)	-2.7 (± 14.8)	4.2 (± 8.0)
C4D1 (n= 7,7,6,6)	-8.7 (± 10.7)	1.0 (± 8.0)	-7.5 (± 6.0)	5.7 (± 20.9)
C5D1 (n= 5,7,6,6)	-13.2 (± 13.2)	2.6 (± 6.9)	-6.7 (± 10.6)	1.5 (± 13.6)
C6D1 (n= 5,5,5,6)	-12.2 (± 9.5)	-0.8 (± 8.3)	-5.4 (± 6.2)	4.3 (± 11.5)
C6D29 (n= 5,5,4,4)	-15.0 (± 13.7)	-2.2 (± 5.3)	-5.3 (± 4.6)	2.3 (± 8.8)

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Stage 2 Main Phase: BMRR**

---

End point title	Stage 2 Main Phase: BMRR <sup>[9]</sup>
-----------------	---

End point description:

Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria at any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy. The all treated population included all participants randomized and who received at least one administration of the drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Up until and including completion of 9 cycles. Each cycle is 28 days.

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	32	32	
Units: Percentage of Participants				
number (confidence interval 95%)	30.3 (14.62 to 45.98)	31.3 (15.19 to 47.31)	25.0 (10.0 to 40.00)	

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Stage 2 Main Phase: BMRR - Reduction of Bone Marrow Fibrosis by Visit**

---

End point title	Stage 2 Main Phase: BMRR - Reduction of Bone Marrow Fibrosis by Visit <sup>[10]</sup>
-----------------	---

End point description:

Reduction in bone marrow fibrosis score: Reduction of at least one grade from baseline. Bone marrow fibrosis grades according to WHO criteria (as determined by central adjudication). The all treated population included all participants randomized and who received at least one administration of the drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 on Cycles 4, 7, 10 and Cycle 9 Day 29. Each cycle is 28 days.

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	32	32	
Units: Percentage of Participants				
number (not applicable)				
Cycle(C) 4 Day(D) 1 (n=28,25,26)	10.7	24.0	19.2	
C7D1 (n=21,17,19)	23.8	11.8	10.5	
C9D29/C10D1 (n=20,14,15)	30.0	21.4	13.3	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Stage 2 Main Phase: Duration of Bone Marrow Improvement

End point title	Stage 2 Main Phase: Duration of Bone Marrow Improvement <sup>[11]</sup>
-----------------	---

End point description:

Duration of response was defined as time from first decrease from baseline  $\geq 1$  grade to time of return to baseline levels. The all treated population included all participants randomized and who received at least one administration of the drug. 9999999 = participants who had bone marrow improvement but did not return to baseline levels at the end of main phase were censored at their last bone marrow assessment in the main phase (the last timepoint in the main phase at which the improvement was still observed).

End point type	Secondary
----------------	-----------

End point timeframe:

From first decrease from baseline of one grade to time of return to baseline levels, up to cycle 9 of 28-day cycles.

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	32	32	
Units: Weeks				
median (confidence interval 95%)	9999999 (12.0 to 9999999)	12.0 (12.0 to 9999999)	12.1 (11.4 to 13.0)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Stage 2 Main Phase: Hemoglobin Improvement

End point title	Stage 2 Main Phase: Hemoglobin Improvement <sup>[12]</sup>
-----------------	--

End point description:

Hemoglobin improvement was measured by the percent of participants with: Red cell transfusion independence (no transfusions for  $\geq 12$  consecutive weeks) OR 50% reduction in red blood cell (RBC) transfusions for  $\geq 12$  consecutive weeks OR percent of participants with  $\geq 10$  g/L and  $\geq 20$  g/L increase in hemoglobin for  $\geq 12$  consecutive weeks without transfusions (outcome parameter assessed was dependent on baseline hemoglobin/transfusion status). The all treated population included all participants randomized and who received at least one administration of the drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Up until and including completion of 9 cycles. Each cycle is 28 days.

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	32	32	
Units: Percentage of Participants				
number (not applicable)	15.2	15.6	6.3	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Stage 2 Main Phase: Platelet Improvement

End point title	Stage 2 Main Phase: Platelet Improvement <sup>[13]</sup>
-----------------	--

End point description:

Platelet improvement was measured by the percent of participants with: Platelet transfusion independence (no transfusions for  $\geq 12$  consecutive weeks) OR 50% reduction in platelets transfusions for  $\geq 12$  consecutive weeks OR doubling of baseline platelet count for  $\geq 12$  consecutive weeks without platelet transfusions OR platelet count  $> 50 \times 10^9/L$  for  $\geq 12$  consecutive weeks without platelet transfusions OR doubling of baseline platelet count for  $\geq 12$  consecutive weeks without platelet transfusions OR platelet count  $> 25 \times 10^9/L$  for  $\geq 12$  consecutive weeks without platelet transfusions (outcome parameter assessed is dependent on baseline platelet status). The all treated population included all participants randomized and who received at least one administration of the drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Up until and including completion of 9 cycles. Each cycle is 28 days.

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	32	32	
Units: Percentage of Participants				
number (not applicable)	27.3	34.4	37.5	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Stage 2 Main Phase: Symptom Improvement

End point title	Stage 2 Main Phase: Symptom Improvement <sup>[14]</sup>
-----------------	---

End point description:

Symptom improvement was assessed as the percent of participants with 50% reduction in MPN-SAF TSS from baseline over time. The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable. The all treated population included all participants randomized and who received at least one administration of the drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Up until and including completion of 9 cycles. Each cycle is 28 days.

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	32	32	
Units: Percentage of Participants				
number (not applicable)				
Cycle(C) 2 Day(D) 1 (n=31, 31, 29)	16.1	6.5	3.4	
C3D1 (n=30, 29, 28)	20.0	10.3	7.1	
C4D1 (n=28, 29, 28)	10.7	13.8	7.1	
C5D1 (n=24, 25, 25)	20.8	8.0	4.0	
C6D1 (n=23, 21, 25)	34.8	14.3	12.0	
C7D1 (n=21, 18, 20)	38.1	27.8	0	
C8D1 (n=20, 18, 19)	25.0	16.7	0	
C9D1 (n=21, 17, 17)	23.8	17.6	5.9	
C9D29/C10D1 (n=20, 16, 13)	25.0	12.5	0	
End of Main Study (n=6, 7, 7)	16.7	0	14.3	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Stage 2 Main Phase: Percentage of Participants with Complete Response (CR), Partial Response (PR), Clinical Improvement (CI), Stable Disease (SD), and Progressive Disease (PD) According to IWG-MRT Criteria

End point title	Stage 2 Main Phase: Percentage of Participants with Complete Response (CR), Partial Response (PR), Clinical Improvement (CI), Stable Disease (SD), and Progressive Disease (PD) According to IWG-MRT Criteria <sup>[15]</sup>
-----------------	---

End point description:

Best Overall Response: (CR Response, PR, CI), SD and PD according to the IWG-MRT Criteria. The all treated population included all participants randomized and who received at least one administration of the drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Up until and including completion of 9 cycles. Each cycle is 28 days.

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	32	32	
Units: Percentage of Participants				
number (not applicable)				
CR	0	0	0	
PR	0	0	0	
CI	24.2	18.8	6.3	
SD	60.6	65.6	81.3	
PD	9.1	9.4	12.5	
Not evaluable	6.1	6.3	0	

## Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Stage 1 Main Phase: Maximum Drug Concentration (Cmax)

End point title	Stage 1 Main Phase: Maximum Drug Concentration (Cmax) <sup>[16]</sup>
-----------------	---

**End point description:**

Cmax is the maximum observed RO7490677 plasma concentration. The PK population included all participants who received at least one dose of rhPTX-2 and had at least one post-dose total PTX-2 concentration result. 9999999 = no samples were analyzed.

End point type	Other pre-specified
----------------	---------------------

**End point timeframe:**

Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

**Notes:**

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6
Units: Micrograms per Milliliter (ug/mL)				
geometric mean (geometric coefficient of variation)				
C1D1 (n=7,7,6,6)	133 (± 48.4)	113 (± 28.1)	164 (± 23.9)	112 (± 90.4)
C1D15 (n=7,0,6,0)	127 (± 31.9)	9999999 (± 9999999)	126 (± 27.5)	9999999 (± 9999999)
C2D1 (n=7,7,6,6)	107 (± 26.9)	110 (± 20.9)	149 (± 29.1)	130 (± 80.2)
C6D1 (n=5,5,5,6)	142 (± 70.0)	111 (± 28.0)	136 (± 34.1)	142 (± 27.4)

**Statistical analyses**

No statistical analyses for this end point

**Other pre-specified: Stage 1 Main Phase: Time to Maximum Concentration (Tmax)**

End point title	Stage 1 Main Phase: Time to Maximum Concentration
-----------------	---

**End point description:**

Time at which the maximum plasma concentration was observed. The PK population included all participants who received at least one dose of rhPTX-2 and had at least one post-dose total PTX-2 concentration result. 9999999 = no samples were analyzed.

End point type	Other pre-specified
----------------	---------------------

**End point timeframe:**

Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

**Notes:**

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6
Units: Hour (hr)				
median (full range (min-max))				
C1D1 (n=7,7,6,6)	1.12 (1.00 to 2.00)	1.10 (1.00 to 2.08)	1.14 (1.00 to 2.25)	1.13 (1.00 to 5.00)
C1D15 (n=7,0,6,0)	1.13 (1.03 to 1.80)	9999999 (9999999 to 9999999)	1.65 (1.02 to 2.50)	9999999 (9999999 to 9999999)
C2D1 (n=7,7,6,6)	1.10 (1.00 to 3.17)	1.08 (1.03 to 1.08)	1.05 (1.00 to 1.32)	1.44 (1.00 to 9.00)
C6D1 (n=5,5,5,6)	2.00 (1.03 to 5.20)	1.07 (1.00 to 2.03)	1.17 (1.05 to 5.00)	1.01 (1.00 to 1.08)

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Stage 1 Main Phase: Area Under the Curve up to the Last Measurable Concentration (AUC0-last)

End point title	Stage 1 Main Phase: Area Under the Curve up to the Last Measurable Concentration (AUC0-last) <sup>[18]</sup>
-----------------	--

End point description:

Area under the plasma concentration time curve from time 0 to time of last measurable plasma concentration. The PK population included all participants who received at least one dose of rhPTX-2 and had at least one post-dose total PTX-2 vconcentration result. 9999999 = no samples were analyzed.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6
Units: ug*hour/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n=7,7,6,6)	1810 (± 72.0)	1690 (± 26.1)	2590 (± 28.7)	1500 (± 158.3)
C1D15 (n=7,0,6,0)	1460 (± 142.0)	9999999 (± 9999999)	2590 (± 187.6)	9999999 (± 9999999)



C2D1 (n=7,7,6,6)	127.3 (± 904)	504 (± 84.7)	2990 (± 92.0)	663 (± 79.5)
C6D1 (n=5,5,5,6)	698 (± 63.0)	570 (± 44.8)	764 (± 28.9)	703 (± 33.8)

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Stage 1 Main Phase: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)

End point title	Stage 1 Main Phase: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) <sup>[19]</sup>
-----------------	---

End point description:

Area under the plasma concentration-time curve from 0-time extrapolated to infinity. The PK population included all participants who received at least one dose of rhPTX-2 and had at least one post-dose total PTX-2 concentration result. 9999999= no samples were analyzed (for C1D15), the geometric mean and geometric coefficient of variation weren't calculated due to terminal phase calculation criteria not being met and the data could not be calculated from data for a single participant.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6
Units: ug*hour/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n=3,7,5,3)	2830 (± 12.9)	2050 (± 29.5)	2970 (± 34.9)	3130 (± 8.6)
C1D15 (n=4,0,4,0)	3450 (± 2.8)	9999999 (± 9999999)	6060 (± 23.2)	9999999 (± 9999999)
C2D1 (n=3,0,5,0)	2170 (± 170.9)	9999999 (± 9999999)	4230 (± 34.8)	9999999 (± 9999999)
C6D1 (n=0,0,1,0)	9999999 (± 9999999)	9999999 (± 9999999)	819 (± 9999999)	9999999 (± 9999999)

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Stage 1 Main Phase: Terminal Elimination Half-Life (T1/2)

End point title	Stage 1 Main Phase: Terminal Elimination Half-Life (T1/2) <sup>[20]</sup>
End point description:	
Apparent terminal elimination half-life of RO7490677. The PK population included all participants who received at least one dose of rhPTX-2 and had at least one post-dose total PTX-2 concentration result. 9999999= no samples were analyzed (for C1D15), the geometric mean and geometric coefficient of variation weren't calculated due to terminal phase calculation criteria not being met and the data could not be calculated from data for a single participant.	
End point type	Other pre-specified
End point timeframe:	
Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days	

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6
Units: hr				
geometric mean (geometric coefficient of variation)				
C1D1 (n=3,7,5,3)	14.7 (± 19.2)	17.2 (± 23.7)	16.8 (± 17.7)	18.4 (± 7.9)
C1D15 (n=4,0,4,0)	31.2 (± 45.0)	9999999 (± 9999999)	40.4 (± 12.6)	9999999 (± 9999999)
C2D1 (n=3,0,5,0)	18.0 (± 220.6)	9999999 (± 9999999)	30.0 (± 48.6)	9999999 (± 9999999)
C6D1 (n=0,0,1,0)	9999999 (± 9999999)	9999999 (± 9999999)	1.95 (± 9999999)	9999999 (± 9999999)

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Stage 1 Main Phase: Clearance (CL)

End point title	Stage 1 Main Phase: Clearance (CL) <sup>[21]</sup>
End point description:	
The PK population included all participants who received at least one dose of rhPTX-2 and had at least one post-dose total PTX-2 concentration result. 9999999= no samples were analyzed (for C1D15), the geometric mean and geometric coefficient of variation weren't calculated due to terminal phase calculation criteria not being met and the data could not be calculated from data for a single participant.	
End point type	Other pre-specified
End point timeframe:	
Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days	

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6
Units: Litres per hour (L/hr)				
geometric mean (geometric coefficient of variation)				
C1D1 (n=3,7,5,3)	0.258 (± 9.0)	0.362 (± 31.5)	0.269 (± 32.9)	0.233 (± 33.3)
C1D15 (n=4,0,4,0)	0.233 (± 24.9)	9999999 (± 9999999)	0.147 (± 35.0)	9999999 (± 9999999)
C2D1 (n=3,0,5,0)	0.382 (± 229.9)	9999999 (± 9999999)	0.189 (± 55.5)	9999999 (± 9999999)
C6D1 (n=0,0,1,0)	9999999 (± 9999999)	9999999 (± 9999999)	1.42 (± 9999999)	9999999 (± 9999999)

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Stage 1 Main Phase: Volume of Distribution (Vd)

End point title	Stage 1 Main Phase: Volume of Distribution (Vd) <sup>[22]</sup>
-----------------	---

End point description:

The PK population included all participants who received at least one dose of rhPTX-2 and had at least one post-dose total PTX-2 concentration result. 9999999= no samples were analyzed (for C1D15), the geometric mean and geometric coefficient of variation weren't calculated due to terminal phase calculation criteria not being met and the data could not be calculated from data for a single participant.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data is being provided for each stage of this study rather than all arms in the baseline period at once.

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	7	6	6
Units: Litres (L)				
geometric mean (geometric coefficient of variation)				
C1D1 (n=3,7,5,3)	5.47 (± 10.9)	9.00 (± 28.8)	6.52 (± 2.64)	6.17 (± 38.9)
C1D15 (n=4,0,4,0)	10.5 (± 62.4)	9999999 (± 9999999)	8.57 (± 47.6)	9999999 (± 9999999)
C2D1 (n=3,0,5,0)	9.93 (± 63.0)	9999999 (± 9999999)	8.18 (± 24.5)	9999999 (± 9999999)

C6D1 (n=0,0,1,0)	9999999 (± 9999999)	9999999 (± 9999999)	4.01 (± 9999999)	9999999 (± 9999999)
------------------	---------------------	---------------------	------------------	---------------------

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Percentage of Participants with Adverse Events (AEs) and Infusion Related Reactions (IRRs)

End point title	Percentage of Participants with Adverse Events (AEs) and Infusion Related Reactions (IRRs)
-----------------	--

End point description:

An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. IRRs were considered to be Adverse Events of Special Interest (AESI). Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0. The safety population included all participants who received at least one dose of study drug.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline up until 6.75 years

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	OLE Stage 1: RO7490677 10 mg/kg IV Q4W	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	13	7	5
Units: Percentage of Participants				
number (not applicable)				
AEs	100	92.3	85.7	100
IRRs	0	7.7	0	20.0

End point values	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	OLE Stage 2: RO7490677 10 mg/kg IV Q4W	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	48	6	33
Units: Percentage of Participants				
number (not applicable)				
AEs	100	89.6	100	100
IRRs	0	2.1	16.7	3.0

<b>End point values</b>	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	32		
Units: Percentage of Participants				
number (not applicable)				
AEs	100	100		
IRRs	3.1	6.3		

### Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Percentage of Participants with Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation

End point title	Percentage of Participants with Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation
-----------------	---

End point description:

An SAE was defined as any AE that occurred at any dose the resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalizations; a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly or birth defect. An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0. The safety population included all participants who received at least one dose of study drug.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline up until 6.75 years

<b>End point values</b>	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)	OLE Stage 1: RO7490677 10 mg/kg IV Q4W	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)	OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	13	7	5
Units: Percentage of Participants				
number (not applicable)				
SAEs	25.0	7.7	0	0
AEs	25.0	30.8	0	0

<b>End point values</b>	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	OLE Stage 2: RO7490677 10 mg/kg IV Q4W	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	48	6	33
Units: Percentage of Participants				
number (not applicable)				
SAEs	0	22.9	0	15.2
AEs	0	27.1	0	21.2

<b>End point values</b>	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	32		
Units: Percentage of Participants				
number (not applicable)				
SAEs	15.6	28.1		
AEs	34.4	37.5		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up until 6.75 years

Adverse event reporting additional description:

Treatment-emergent adverse events (TEAEs) were defined as any AE that occurred after the administration of any amount of the study drug, or any event that was present at baseline.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

### Reporting groups

Reporting group title	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W
-----------------------	--

Reporting group description:

Participants were treated with single agent PRM-151 at a dose of 0.3 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib
-----------------------	--

Reporting group description:

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)
-----------------------	---

Reporting group description:

Participants who received no treatment for Myelofibrosis (MF) in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 milligram per kilogram (mg/kg) administered as a 30 minute intravenous (IV) infusion on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Reporting group title	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W
-----------------------	---

Reporting group description:

Participants were treated with single agent PRM-151 at a dose of 10 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Reporting group title	OLE Stage 2: RO7490677 10 mg/kg IV Q4W
-----------------------	--

Reporting group description:

Participants who completed 9 cycles of the originally assigned treatment could switch to the open label extension. Participants enrolled received PRM-151 at a dose of 10mg/kg Q4W on days 1, 3, and 5 of first cycle of the open label phase and Day 1 of each subsequent 28 day cycle.

Reporting group title	OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib
-----------------------	--

Reporting group description:

Participants who completed the main phase of treatment moved to the open label extension. They were treated with PRM-151 at a dose of 10 mg/kg administered as an IV infusion in combination with daily oral ruxolitinib on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle.

Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
-----------------------	--

Reporting group description:

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks were assigned to receive PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion in combination with daily oral ruxolitinib on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

Reporting group title	OLE Stage 1: RO7490677 10 mg/kg IV Q4W
-----------------------	--

Reporting group description:

Participants who completed the main phase of treatment moved to the open label extension. They were

treated with single agent PRM-151 at a dose of 10 mg/kg administered as an IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle.

Reporting group title	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)
-----------------------	---

Reporting group description:

Participants who received no treatment for MF in at least two weeks were assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg administered as a 30 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

Reporting group title	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W
-----------------------	--

Reporting group description:

Participants were treated with single agent PRM-151 at a dose of 3.0 mg/kg administered as a 60 minute IV infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

<b>Serious adverse events</b>	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 33 (33.33%)	2 / 6 (33.33%)	2 / 8 (25.00%)
number of deaths (all causes)	7	1	2
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cancer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelofibrosis			



subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Primary myelofibrosis			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transformation to acute myeloid leukaemia			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Vascular disorders			
Dry gangrene			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Aortic valve replacement			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Peripheral swelling			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Unevaluable event			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Eastern Cooperative Oncology Group performance status worsened			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoradionecrosis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac failure			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic encephalopathy			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone marrow failure			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extramedullary haemopoiesis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia, obstructive			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal ischaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal varices haemorrhage			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal hypertension			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			



Eczema			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Urinary bladder haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder rupture			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Chondrocalcinosis pyrophosphate			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma muscle			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 33 (6.06%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pneumonia fungal			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pseudomonal sepsis			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sialoadenitis			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperuricaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	OLE Stage 2: RO7490677 10 mg/kg IV Q4W	OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib
Total subjects affected by serious adverse events			
subjects affected / exposed	14 / 32 (43.75%)	22 / 48 (45.83%)	2 / 5 (40.00%)
number of deaths (all causes)	9	7	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatic cancer			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			

subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelofibrosis			
subjects affected / exposed	1 / 32 (3.13%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Primary myelofibrosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transformation to acute myeloid leukaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Dry gangrene			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			

Aortic valve replacement subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	2 / 32 (6.25%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Inflammation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral swelling			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Unevaluable event			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Investigations			
Eastern Cooperative Oncology Group performance status worsened			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			



subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoradionecrosis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			

subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Nervous system disorders			
Cerebral haemorrhage			

subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic encephalopathy			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Syncope			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 32 (0.00%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone marrow failure			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Extramedullary haemopoiesis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			

subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia, obstructive			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Intestinal ischaemia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth haemorrhage			

subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal hypertension			

subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder rupture			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Back pain			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma muscle			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Joint effusion			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Enterocolitis infectious			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 32 (0.00%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 32 (6.25%)	3 / 48 (6.25%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia fungal			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			



subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal sepsis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sialoadenitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			

subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperuricaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib	OLE Stage 1: RO7490677 10 mg/kg IV Q4W	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	5 / 13 (38.46%)	1 / 7 (14.29%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cancer			

subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelofibrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Primary myelofibrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transformation to acute myeloid leukaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Dry gangrene			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			

subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Aortic valve replacement			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Peripheral swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Unevaluable event			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Eastern Cooperative Oncology Group performance status worsened			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoradionecrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
Cerebral haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic encephalopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
Anaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone marrow failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extramedullary haemopoiesis			



subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia, obstructive			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal ischaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal hypertension			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder rupture			

subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma muscle			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Abscess limb			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Endocarditis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia fungal			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal sepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sialoadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperuricaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W		
Total subjects affected by serious adverse events			
subjects affected / exposed	14 / 32 (43.75%)		
number of deaths (all causes)	6		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic cancer			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant neoplasm progression			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myelofibrosis			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Primary myelofibrosis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transformation to acute myeloid leukaemia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Dry gangrene			



subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematoma			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Aortic valve replacement			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Disease progression			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inflammation			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Organ failure			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral swelling			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Unevaluable event			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Eastern Cooperative Oncology Group performance status worsened			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic enzyme increased			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Infusion related reaction			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple fractures			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoradionecrosis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural haematoma			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Procedural haemorrhage			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rib fracture			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subdural haematoma			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic valve stenosis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac arrest			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiopulmonary failure			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery disease			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericardial effusion			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hepatic encephalopathy			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolic encephalopathy			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bone marrow failure			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Extramedullary haemopoiesis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukocytosis			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancytopenia			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Thrombocytopenia			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femoral hernia, obstructive			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal ischaemia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Melaena			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mouth haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Varices oesophageal			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			

subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Portal hypertension			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin ulcer			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary bladder haemorrhage			



subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary bladder rupture			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemarthrosis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematoma muscle			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint effusion			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Cellulitis				
subjects affected / exposed	1 / 32 (3.13%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Endocarditis				
subjects affected / exposed	1 / 32 (3.13%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Enterocolitis infectious				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral discitis				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteomyelitis				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				

subjects affected / exposed	1 / 32 (3.13%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Pneumonia fungal				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia viral				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pseudomonal sepsis				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory syncytial virus infection				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Septic shock				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sialoadenitis				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				

subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Wound infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperuricaemia			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W	Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib	Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 33 (96.97%)	6 / 6 (100.00%)	8 / 8 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lipoma			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neoplasm			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Hot flush			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Chest discomfort			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Chest pain			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Early satiety			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Extravasation			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	8 / 33 (24.24%)	1 / 6 (16.67%)	3 / 8 (37.50%)
occurrences (all)	9	3	3
Gait disturbance			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Ill-defined disorder			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Injection site haemorrhage			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Oedema peripheral			
subjects affected / exposed	6 / 33 (18.18%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	8	0	0
Pain			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Peripheral swelling			
subjects affected / exposed	2 / 33 (6.06%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	3	1	0
Pyrexia			
subjects affected / exposed	4 / 33 (12.12%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	4	0	0
Swelling			

subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Vessel puncture site bruise subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	2 / 6 (33.33%) 5	0 / 8 (0.00%) 0
Social circumstances Blood product transfusion dependent subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Reproductive system and breast disorders Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	10 / 33 (30.30%) 12	2 / 6 (33.33%) 2	1 / 8 (12.50%) 1
Dysphonia subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	4 / 33 (12.12%) 7	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Dyspnoea exertional subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 7	2 / 6 (33.33%) 3	0 / 8 (0.00%) 0
Hypoxia subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1
Nasal dryness subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0
Oropharyngeal pain			

subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Paranasal sinus discomfort			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sneezing			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 33 (3.03%)	1 / 6 (16.67%)	1 / 8 (12.50%)
occurrences (all)	1	1	1
Sleep disorder			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0



Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	3 / 8 (37.50%)
occurrences (all)	2	0	3
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	6	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood sodium decreased			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Blood urea increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	2
Neutrophil count decreased			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Platelet count decreased			
subjects affected / exposed	4 / 33 (12.12%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	8	0	0
Weight decreased			

subjects affected / exposed	6 / 33 (18.18%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	7	0	0
Weight increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	5	0	0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Contusion			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Foot fracture			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Post-traumatic pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Procedural pain			

subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Road traffic accident			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Wound			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Wrist fracture			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	6 / 33 (18.18%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	9	1	0
Headache			
subjects affected / exposed	4 / 33 (12.12%)	2 / 6 (33.33%)	0 / 8 (0.00%)
occurrences (all)	5	2	0
Hypoaesthesia			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Nerve compression			

subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Neuropathy peripheral			
subjects affected / exposed	3 / 33 (9.09%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Sciatic nerve neuropathy			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Sciatica			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 33 (15.15%)	1 / 6 (16.67%)	1 / 8 (12.50%)
occurrences (all)	11	1	1
Increased tendency to bruise			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Leukocytosis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Thrombocytopenia			
subjects affected / exposed	5 / 33 (15.15%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	6	1	0
Eye disorders			
Dry eye			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	3 / 33 (9.09%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Abdominal pain			
subjects affected / exposed	5 / 33 (15.15%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	7	0	2
Abdominal pain lower			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	2
Abdominal pain upper			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Abdominal tenderness			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	4 / 33 (12.12%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	5	0	0
Diarrhoea			
subjects affected / exposed	8 / 33 (24.24%)	0 / 6 (0.00%)	2 / 8 (25.00%)
occurrences (all)	8	0	2

Flatulence			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Gingival pain			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	2 / 33 (6.06%)	1 / 6 (16.67%)	2 / 8 (25.00%)
occurrences (all)	2	1	2
Oral disorder			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	2
Oral pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Retching			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	1 / 33 (3.03%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Vomiting			
subjects affected / exposed	1 / 33 (3.03%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Hepatosplenomegaly			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Ecchymosis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Hyperkeratosis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Lichen planus			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Petechiae			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Pruritus			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Rash erythematous			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Rash pruritic subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Skin induration subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Nocturia subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0
Bone pain subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0



Groin pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Joint lock			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Joint swelling			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Muscle spasms			
subjects affected / exposed	3 / 33 (9.09%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Muscular weakness			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	2
Musculoskeletal chest pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	3 / 33 (9.09%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	3	0	1
Neck pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	2 / 33 (6.06%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	3	2	0
Infections and infestations			
Bronchitis			

subjects affected / exposed	3 / 33 (9.09%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	5	0	0
Cellulitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Diarrhoea infectious			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Localised infection			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Lyme disease			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Oral herpes			
subjects affected / exposed	0 / 33 (0.00%)	2 / 6 (33.33%)	1 / 8 (12.50%)
occurrences (all)	0	2	1
Pneumonia			
subjects affected / exposed	3 / 33 (9.09%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	4	0	0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rhinitis			

subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sialoadenitis			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Sinusitis			
subjects affected / exposed	2 / 33 (6.06%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Skin infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Tooth infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 33 (6.06%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	2	1	0
Urinary tract infection			
subjects affected / exposed	2 / 33 (6.06%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	4	2	0
Urosepsis			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	4 / 33 (12.12%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	5	0	0

Gout			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Hyperglycaemia			
subjects affected / exposed	3 / 33 (9.09%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	4	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	1 / 33 (3.03%)	0 / 6 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Hypocalcaemia			
subjects affected / exposed	1 / 33 (3.03%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Hypokalaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Iron overload			
subjects affected / exposed	0 / 33 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 33 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W	OLE Stage 2: RO7490677 10 mg/kg IV Q4W	OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib
Total subjects affected by non-serious adverse events			
subjects affected / exposed	31 / 32 (96.88%)	32 / 48 (66.67%)	5 / 5 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Lipoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Neoplasm			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	3 / 5 (60.00%)
occurrences (all)	0	0	3
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Hypotension			
subjects affected / exposed	1 / 32 (3.13%)	3 / 48 (6.25%)	0 / 5 (0.00%)
occurrences (all)	1	3	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 32 (6.25%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences (all)	2	2	0
Chest discomfort			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Early satiety			

subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Extravasation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	11 / 32 (34.38%)	5 / 48 (10.42%)	0 / 5 (0.00%)
occurrences (all)	12	5	0
Gait disturbance			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
Ill-defined disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Injection site haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	9 / 32 (28.13%)	4 / 48 (8.33%)	0 / 5 (0.00%)
occurrences (all)	10	5	0
Pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	2 / 32 (6.25%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Pyrexia			
subjects affected / exposed	3 / 32 (9.38%)	2 / 48 (4.17%)	1 / 5 (20.00%)
occurrences (all)	3	3	2
Swelling			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Vessel puncture site bruise			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Social circumstances			

Blood product transfusion dependent subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Reproductive system and breast disorders Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 5	4 / 48 (8.33%) 4	3 / 5 (60.00%) 4
Dysphonia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	7 / 32 (21.88%) 8	4 / 48 (8.33%) 4	0 / 5 (0.00%) 0
Dyspnoea exertional subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 11	7 / 48 (14.58%) 16	1 / 5 (20.00%) 1
Hypoxia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Nasal dryness subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 48 (2.08%) 1	1 / 5 (20.00%) 1
Paranasal sinus discomfort subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Pleural effusion			

subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Pneumothorax			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sneezing			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Psychiatric disorders			
Delirium			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	1 / 32 (3.13%)	3 / 48 (6.25%)	0 / 5 (0.00%)
occurrences (all)	1	3	0
Insomnia			
subjects affected / exposed	0 / 32 (0.00%)	3 / 48 (6.25%)	0 / 5 (0.00%)
occurrences (all)	0	3	0
Sleep disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	2 / 5 (40.00%)
occurrences (all)	1	0	2
Aspartate aminotransferase increased			



subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	2 / 5 (40.00%)
occurrences (all)	1	0	2
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 32 (0.00%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences (all)	0	2	0
Blood bilirubin increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	2 / 5 (40.00%)
occurrences (all)	0	0	3
Blood creatinine increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood sodium decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
Platelet count decreased			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	2	1	0
Weight decreased			
subjects affected / exposed	8 / 32 (25.00%)	5 / 48 (10.42%)	0 / 5 (0.00%)
occurrences (all)	11	6	0
Weight increased			
subjects affected / exposed	0 / 32 (0.00%)	3 / 48 (6.25%)	0 / 5 (0.00%)
occurrences (all)	0	3	0

White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	3 / 48 (6.25%) 3	0 / 5 (0.00%) 0
Injury, poisoning and procedural complications			
Ankle fracture subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	1 / 5 (20.00%) 1
Arthropod bite subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	5 / 48 (10.42%) 5	1 / 5 (20.00%) 3
Eye contusion subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3	3 / 48 (6.25%) 6	0 / 5 (0.00%) 0
Foot fracture subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Infusion related reaction subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	1 / 5 (20.00%) 1
Post-traumatic pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Procedural pain subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Road traffic accident subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Transfusion reaction			

subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Wrist fracture			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 32 (3.13%)	2 / 48 (4.17%)	1 / 5 (20.00%)
occurrences (all)	1	2	1
Headache			
subjects affected / exposed	3 / 32 (9.38%)	3 / 48 (6.25%)	2 / 5 (40.00%)
occurrences (all)	3	3	4
Hypoaesthesia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Nerve compression			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
Sciatic nerve neuropathy			

subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	1 / 5 (20.00%) 1
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 6	6 / 48 (12.50%) 12	1 / 5 (20.00%) 1
Increased tendency to bruise subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	1 / 5 (20.00%) 1
Leukopenia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	1 / 48 (2.08%) 1	0 / 5 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	2 / 48 (4.17%) 2	0 / 5 (0.00%) 0
Splenomegaly subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3	7 / 48 (14.58%) 7	0 / 5 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	2 / 48 (4.17%) 3	0 / 5 (0.00%) 0
Eye disorders			
Dry eye subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 48 (2.08%) 1	0 / 5 (0.00%) 0
Vision blurred subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Gastrointestinal disorders			

Abdominal discomfort			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	2 / 32 (6.25%)	1 / 48 (2.08%)	1 / 5 (20.00%)
occurrences (all)	2	1	1
Abdominal pain			
subjects affected / exposed	4 / 32 (12.50%)	3 / 48 (6.25%)	0 / 5 (0.00%)
occurrences (all)	5	3	0
Abdominal pain lower			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 32 (3.13%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences (all)	2	2	0
Abdominal tenderness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	4 / 32 (12.50%)	3 / 48 (6.25%)	0 / 5 (0.00%)
occurrences (all)	6	3	0
Diarrhoea			
subjects affected / exposed	3 / 32 (9.38%)	7 / 48 (14.58%)	1 / 5 (20.00%)
occurrences (all)	3	7	1
Flatulence			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Gingival bleeding subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 48 (2.08%) 1	0 / 5 (0.00%) 0
Gingival pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 5	3 / 48 (6.25%) 5	2 / 5 (40.00%) 3
Oral disorder subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Oral pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Retching subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	3 / 48 (6.25%) 4	0 / 5 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 9	0 / 48 (0.00%) 0	2 / 5 (40.00%) 2
Hepatobiliary disorders Hepatomegaly subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Hepatosplenomegaly subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 48 (0.00%) 0	1 / 5 (20.00%) 1
Skin and subcutaneous tissue disorders			

Ecchymosis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Hyperhidrosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Lichen planus			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
Petechiae			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	3 / 32 (9.38%)	3 / 48 (6.25%)	0 / 5 (0.00%)
occurrences (all)	3	3	0
Rash			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Rash erythematous			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Skin induration			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Skin lesion subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Nocturia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	1 / 5 (20.00%) 1
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	3 / 48 (6.25%) 3	4 / 5 (80.00%) 4
Back pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 48 (2.08%) 1	1 / 5 (20.00%) 1
Bone pain subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 48 (0.00%) 0	1 / 5 (20.00%) 1
Groin pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Joint lock subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0



Joint swelling			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 32 (0.00%)	3 / 48 (6.25%)	1 / 5 (20.00%)
occurrences (all)	0	3	1
Muscular weakness			
subjects affected / exposed	2 / 32 (6.25%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	1 / 32 (3.13%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences (all)	1	2	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Myalgia			
subjects affected / exposed	2 / 32 (6.25%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	2	2	0
Neck pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 48 (0.00%)	2 / 5 (40.00%)
occurrences (all)	1	0	2
Cellulitis			
subjects affected / exposed	1 / 32 (3.13%)	4 / 48 (8.33%)	0 / 5 (0.00%)
occurrences (all)	2	5	0
Diarrhoea infectious			

subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Folliculitis			
subjects affected / exposed	2 / 32 (6.25%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Localised infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lyme disease			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	2 / 32 (6.25%)	3 / 48 (6.25%)	1 / 5 (20.00%)
occurrences (all)	3	3	1
Oral herpes			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	3 / 32 (9.38%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	3	1	0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sialoadenitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sinusitis			

subjects affected / exposed	0 / 32 (0.00%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	0	2	0
Skin infection			
subjects affected / exposed	2 / 32 (6.25%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 32 (0.00%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences (all)	0	5	0
Urinary tract infection			
subjects affected / exposed	1 / 32 (3.13%)	4 / 48 (8.33%)	0 / 5 (0.00%)
occurrences (all)	1	4	0
Urosepsis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 48 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	4 / 32 (12.50%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences (all)	6	2	0
Gout			
subjects affected / exposed	1 / 32 (3.13%)	1 / 48 (2.08%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
Hyperglycaemia			
subjects affected / exposed	1 / 32 (3.13%)	2 / 48 (4.17%)	0 / 5 (0.00%)
occurrences (all)	2	3	0

Hyperphosphataemia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	1 / 48 (2.08%) 1	0 / 5 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	1 / 48 (2.08%) 2	1 / 5 (20.00%) 1
Hypomagnesaemia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	1 / 5 (20.00%) 3
Iron deficiency subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Iron overload subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0
Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 48 (0.00%) 0	0 / 5 (0.00%) 0

<b>Non-serious adverse events</b>	Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib	OLE Stage 1: RO7490677 10 mg/kg IV Q4W	Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 6 (100.00%)	12 / 13 (92.31%)	6 / 7 (85.71%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lipoma subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 13 (7.69%) 1	0 / 7 (0.00%) 0
Neoplasm subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 13 (7.69%) 1	0 / 7 (0.00%) 0

Squamous cell carcinoma subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Vascular disorders			
Haematoma subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 13 (7.69%) 1	0 / 7 (0.00%) 0
Hot flush subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Hypertension subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Hypotension subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 13 (0.00%) 0	1 / 7 (14.29%) 1
Chest discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Chest pain subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Chills subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 13 (7.69%) 2	0 / 7 (0.00%) 0
Early satiety subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	1 / 13 (7.69%) 1	0 / 7 (0.00%) 0
Extravasation subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Fatigue			

subjects affected / exposed	1 / 6 (16.67%)	2 / 13 (15.38%)	1 / 7 (14.29%)
occurrences (all)	1	2	1
Gait disturbance			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ill-defined disorder			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Injection site haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 6 (0.00%)	2 / 13 (15.38%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	2 / 6 (33.33%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Pyrexia			
subjects affected / exposed	3 / 6 (50.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	3	0	0
Swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site bruise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Social circumstances			
Blood product transfusion dependent			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			

Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 13 (7.69%) 1	0 / 7 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	2 / 13 (15.38%) 3	0 / 7 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	2 / 7 (28.57%) 2
Dyspnoea exertional subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Hypoxia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Nasal dryness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Paranasal sinus discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 13 (7.69%) 1	0 / 7 (0.00%) 0
Pleural effusion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Pneumothorax			

subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Rhinitis allergic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Sleep apnoea syndrome			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Sneezing			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Sleep disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			



subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Blood sodium decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
White blood cell count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Eye contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Foot fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Infusion related reaction			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Post-traumatic pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Procedural pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Road traffic accident			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	3	0	0
Transfusion reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Wound			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Wrist fracture			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 6 (16.67%)	2 / 13 (15.38%)	0 / 7 (0.00%)
occurrences (all)	1	3	0
Hypoaesthesia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Nerve compression			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	2
Sciatic nerve neuropathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Sciatica			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 6 (16.67%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	1	2	0
Increased tendency to bruise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	0 / 6 (0.00%)	3 / 13 (23.08%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Abdominal distension			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Abdominal pain lower			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	3 / 13 (23.08%)	0 / 7 (0.00%)
occurrences (all)	0	4	0
Abdominal tenderness			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Anal incontinence			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	2 / 6 (33.33%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 6 (16.67%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Gingival bleeding			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gingival pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	4 / 13 (30.77%)	1 / 7 (14.29%)
occurrences (all)	0	5	1
Oral disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Retching			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Stomatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	2 / 13 (15.38%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hepatosplenomegaly			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Ecchymosis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Erythema			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lichen planus			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Rash erythematous			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Rash pruritic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Skin induration			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Skin lesion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urticaria			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 13 (0.00%) 0	0 / 7 (0.00%) 0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Nocturia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 6 (16.67%)	2 / 13 (15.38%)	0 / 7 (0.00%)
occurrences (all)	1	2	0
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Bone pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Groin pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Joint lock			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Muscle spasms			



subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Musculoskeletal chest pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Diarrhoea infectious			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Gastroenteritis viral			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Laryngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Localised infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lyme disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Oral herpes			
subjects affected / exposed	1 / 6 (16.67%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Rhinitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Sialoadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Skin infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0

Subcutaneous abscess			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 6 (33.33%)	3 / 13 (23.08%)	0 / 7 (0.00%)
occurrences (all)	2	4	0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	2 / 13 (15.38%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Urosepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Gout			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hyperphosphataemia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hyperuricaemia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Iron overload			
subjects affected / exposed	0 / 6 (0.00%)	0 / 13 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 6 (0.00%)	1 / 13 (7.69%)	0 / 7 (0.00%)
occurrences (all)	0	1	0

<b>Non-serious adverse events</b>	Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 32 (93.75%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lipoma			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Neoplasm			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Squamous cell carcinoma			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Vascular disorders			

Haematoma			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Hot flush			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Hypotension			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	4		
Chest discomfort			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	3		
Chest pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Chills			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	5		
Early satiety			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Extravasation			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	8 / 32 (25.00%)		
occurrences (all)	10		
Gait disturbance			

subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Ill-defined disorder			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Injection site haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	4		
Pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Peripheral swelling			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	7 / 32 (21.88%)		
occurrences (all)	8		
Swelling			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Vessel puncture site bruise			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Social circumstances			
Blood product transfusion dependent			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	7 / 32 (21.88%)		
occurrences (all)	8		
Dysphonia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	8 / 32 (25.00%)		
occurrences (all)	10		
Dyspnoea exertional			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Epistaxis			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	4		
Hypoxia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Nasal dryness			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	4		
Paranasal sinus discomfort			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Pleural effusion			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Pneumothorax			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Rhinitis allergic			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		

Sleep apnoea syndrome subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Sneezing subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Upper-airway cough syndrome subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Psychiatric disorders Delirium subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3		
Depression subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4		
Insomnia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1		
Sleep disorder subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 7		
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 9		
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 4		
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Blood creatine phosphokinase increased			



subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Blood creatinine increased			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Blood sodium decreased			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Blood urea increased			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Blood uric acid increased			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Neutrophil count decreased			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	4		
Platelet count decreased			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	3		
Weight decreased			
subjects affected / exposed	8 / 32 (25.00%)		
occurrences (all)	8		
Weight increased			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
White blood cell count decreased			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Arthropod bite			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Contusion			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Eye contusion			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Fall			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	7		
Foot fracture			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Infusion related reaction			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Post-traumatic pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Procedural pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Road traffic accident			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Transfusion reaction			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Wound			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Wrist fracture			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Cardiac disorders			

Palpitations			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Supraventricular extrasystoles			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Nervous system disorders			
Dizziness			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	3		
Headache			
subjects affected / exposed	7 / 32 (21.88%)		
occurrences (all)	8		
Hypoaesthesia			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Nerve compression			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Neuropathy peripheral			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Sciatic nerve neuropathy			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Sciatica			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	6 / 32 (18.75%)		
occurrences (all)	8		
Increased tendency to bruise			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Leukocytosis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Leukopenia			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Neutropenia			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	3		
Splenomegaly			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	3		
Thrombocytopenia			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	5		
Eye disorders			
Dry eye			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	3		
Vision blurred			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Abdominal distension			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	6 / 32 (18.75%)		
occurrences (all)	8		
Abdominal pain lower			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Abdominal tenderness			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Anal incontinence			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Aphthous ulcer			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	4		
Diarrhoea			
subjects affected / exposed	5 / 32 (15.63%)		
occurrences (all)	5		
Flatulence			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Gingival bleeding			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Gingival pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Oral disorder			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Oral pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Retching			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Stomatitis			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Vomiting			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	3		
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Hepatosplenomegaly			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Hyperbilirubinaemia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Ecchymosis			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Erythema			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Hyperkeratosis			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Lichen planus			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Night sweats			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	7		
Petechiae			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	6		
Rash			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Rash erythematous			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Rash pruritic			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Skin induration			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Skin lesion			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Urticaria			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		

Haematuria subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Nocturia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 5		
Back pain subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3		
Bone pain subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3		
Groin pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Joint lock subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Joint swelling subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Muscle spasms subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3		
Muscular weakness subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 2		
Musculoskeletal chest pain			



subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Musculoskeletal pain			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	3		
Musculoskeletal stiffness			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	5 / 32 (15.63%)		
occurrences (all)	5		
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Diarrhoea infectious			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Folliculitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Gastroenteritis viral			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Laryngitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		

Localised infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Lyme disease			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Oral herpes			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Pneumonia			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Rhinitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Sialoadenitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Sinusitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Skin infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Subcutaneous abscess			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Tooth infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		

Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Urosepsis subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Metabolism and nutrition disorders			
Cachexia subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Decreased appetite subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 5		
Gout subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Hyperglycaemia subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 5		
Hyperphosphataemia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Hyperuricaemia subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 5		
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Hypokalaemia			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Hypomagnesaemia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Iron deficiency			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Iron overload			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 February 2013	The protocol was amended to clarify that participants could switch to different treatment arms after the completion of 6 cycles and that participants were evaluable for response after 4 weeks of treatment. The requirement for post infusion observation changed to four hours (from one hour) after all doses of PRM-151 through Cycle 2, Day 1 and for one hour after each subsequent dose. Specific instructions were provided for slowing or stopping PRM-151 infusion and for prophylaxis of infusion reactions (IR) for those who experienced IR(s). The IWG response criteria was assigned to the efficacy and some safety assessments. Gradation of treatment emergent non-hematological AEs considered applicable for the stopping rules to grade 3 was lowered. The timing of vital sign assessments were changed. Anti-drug antibody levels on Days 15 and 22 of Cycle 1 was included for participants receiving QW PRM-151, and on Day 15 for participants receiving Q4W dosing of PRM-151. The number of PK samples required was reduced.
10 May 2013	Added a summary of the acute infusion reactions seen in chronic toxicology studies and a summary of the root cause analysis and risk mitigation plan for humans; modified the PRM-151 infusion rate from 30 minutes to 60 minutes; clarified that participants in Cohort 2, receiving ruxolitinib should avoid strong CYP3A4 inhibitors; clarified that all acute infusion reactions should be managed according to guidelines; added Electrocardiogram (ECG) assessments at Day 1 of each cycle; clarified that if a participant experienced an acute infusion related reaction, a sample for anti-pentraxin-2 antibodies and a sample for cytokines would be collected; updated classification structure of AEs; increased safety surveillance measures; clarified that AEs would be followed beyond 30 days after the last dose if needed; clarified sample size calculations; clarified that no comparisons between treatment arms were to be performed; clarified that all participants that discontinued prior to completing 1 cycle of treatment were considered non responders; clarified that all participants that received at least 1 exposure to PRM-151 were included in the safety set; added the use of a Data Monitoring Committee (DMC).
14 February 2014	This protocol amendment clarified that stable disease with improvement in bone marrow fibrosis was called a bone marrow response. The requirements for continuing in the OLE portion of the study were included along with the dose calculated based on the participant's weight of Day 1 of each cycle. It explained that although serious adverse events (SAEs) were captured from time of informed consent, only for participants that received at least one dose of PRM-151; SAEs in screen failures were not captured. A post infusion ECG for Cycle 6 only for Day 1 (both weekly and every 4 weekly schedules) and Day 15 (weekly schedule only) was added. A clarification that Response Assessments were performed on Day 1 of each cycle and that the first post dose PK sample was at the end of the 60 minute infusion. Revised response criteria for myelofibrosis based on the IWG-MRT and European LeukemiaNet (ELN) consensus report was included into this amendment.

04 May 2015	The protocol was amended to remove "Open Label" from the title of the study. The primary, secondary and exploratory objectives and endpoints were modified and additional exploratory objectives and endpoints were included. There were revisions to the study design. Modifications were made to the inclusion criteria as well as creating additional exclusion criteria. Efficacy assessments were modified by using the World Health Organization (WHO) bone marrow fibrosis grade, changes in hemoglobin, platelets, peripheral blood blasts, disease related symptoms, and spleen size. The role of the Data Monitoring Committee was clarified for Stage 2. The dosing amount for the study drug as well as the timing of the dose was modified and the use of ruxolitinib was clarified in this amendment. The method for assigning participants to treatment groups was clarified. Information regarding study blinding, and the procedure for breaking the blind was added. Removed the concomitant medication ruxolitinib and the requirement to record self administration of ruxolitinib. JAK kinase inhibitors were added to the list of excluded concomitant medications. The European Consensus on Grading of Bone Marrow Fibrosis to the WHO criteria for bone marrow fibrosis was revised. Testing for Cytokines and levels of mRNA and miRNA was removed and genetic testing of JAK2V617F, MPLW515, Calreticulin, ASXL1, EZH2, SRSF2, IDH1/2 was included. Information regarding the OLE portion of the study was included. The requirement to maintain a diary for all red blood cell (RBC) and platelet transfusions was added and the requirements for bone marrow biopsy and aspirate were updated. The reporting requirements and contact information for Adverse Events of Special Interest (AESIs) and reporting SAEs were updated.
15 December 2016	The protocol amendment added a loading dose for in participants in Stage 2 OLE portion of the study. Additional safety information from the IPF trial was included. Added clarification that DNA sampling was not mandatory for participants was added along with the note that the baseline blood sample for DNA sampling would also be used for the cytogenetic analysis. Removed cytogenetic analysis on marrow biopsy/aspirate. Modified the units of measurement of serum creatinine and clarified that spleen size would be measures by CT or MRI. Added clarification for contraception and adding highly effective methods to align with IB v10, which laboratories were considered central or local and information regarding pregnancy-testing requirements. Clarified that PRM-151 could be resumed when AE had resolved to Grade 1 or baseline. Added anti-pentraxin 2 antibodies collection for IRR and anti-pentraxin 2 antibodies and cytokines in the event of a suspected AE. Serious Treatment Emergent AEs (TEAEs) were removed from this version of the protocol. Clarification was added to allow for a wider visit window and to clarify window for visit, imaging procedures, laboratory assessments, transfusion diary and response assessments during Cycle 2 through 9, Day 1 as well as a wider visit window and to clarify the window allowed for visit, lab collection, transfusion diary recording at the end of study.

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported